Economic Burden and Health Care Resource Utilization of Patients With Eosinophilic Esophagitis in the United States
Mirna Chehade(New York Proton Center), Ryan B. Thomas(Regeneron (United States)), Tiffany Pela(Sanofi (United States)), Andrew J. Epstein(Veterans Health Administration), Eilish McCann(Northwestern University), Chao Chen(Regeneron (United States)), Angela Khodzhayev(Regeneron (United States)), Degang Wang(Regeneron (United States)), Sarette T. Tilton(Sanofi (United States))
Cited by 3
Related Papers
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
|New England Journal of Medicine|2024|107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2023|100
Impact of Minimally Invasive Surgery on Medical Spending and Employee Absenteeism
|JAMA Surgery|2013|74